<p>BioNTech（纳斯达克代码：BNTX - 获取免费报告）的股票在周二发布给投资者的研究报告中被 Weiss Ratings 的研究分析师重申了 “卖出（d-）” 评级，Weiss Ratings 报道。</p>
<ul>
<li>4 个理由说明辉瑞可能是你不能错过的价值投资</li>
</ul>
<p>其他一些研究分析师也对该公司发表了看法。摩根大通将 BioNTech 的目标价从 116.00 美元上调至 121.00 美元，并在 9 月 22 日的研究报告中给予该股票 “中性” 评级。HC Wainwright 在 9 月 8 日的研究报告中重申了 “买入” 评级，并设定了 BioNTech 股票的目标价为 136.00 美元。美国银行在 8 月 5 日的报告中将 BioNTech 股票的目标价从 126.00 美元上调至 134.00 美元，并给予该股票 “买入” 评级。摩根士丹利在周五的报告中将 BioNTech 股票的目标价从 133.00 美元下调至 131.00 美元，并对该股票设定了 “增持” 评级。最后，富国银行在 8 月 5 日的研究报告中设定了 BioNTech 股票的目标价为 150.00 美元，并给予该股票 “增持” 评级。十位研究分析师对该股票给予了 “买入” 评级，三位给予了 “持有” 评级，一位给予了 “卖出” 评级。根据 MarketBeat 的数据，该股票的共识评级为 “适度买入”，共识目标价为 134.32 美元。</p>
<p><strong>获取我们对 BioNTech 的最新股票分析</strong></p>
<h2>BioNTech 上涨 0.2%</h2>
<ul>
<li>Moderna 因第二季度收益下滑而下跌，但它能否因空头回补而反弹？</li>
</ul>
<p>纳斯达克：BNTX 在周二上涨 0.25 美元，达到 102.55 美元。该股票的交易量为 217,329 股，而其平均交易量为 950,002 股。该公司的市值为 246.5 亿美元，市盈率为-64.21，贝塔值为 1.45。该公司的债务与股本比率为 0.01，流动比率为 8.61，速动比率为 8.48。该公司的 50 日移动平均线为 104.32 美元，200 日移动平均线为 103.68 美元。BioNTech 的 12 个月低点为 81.20 美元，12 个月高点为 129.27 美元。</p>
<p>BioNTech（纳斯达克代码：BNTX - 获取免费报告）最后一次发布财报是在 8 月 4 日，周一。该公司报告的每股收益（EPS）为-1.60 美元，低于分析师的共识预期-1.41 美元，差距为 0.19 美元。该公司在该季度的收入为 3.0646 亿美元，而分析师的预期为 1.6126 亿美元。BioNTech 的净利润率为-12.20%，股本回报率为-1.84%。BioNTech 在该季度的收入同比增长了 102.6%。去年同期，该公司每股收益为-3.36 美元。BioNTech 已设定其 2025 财年的指导目标为每股收益。股票分析师预计 BioNTech 在当前财年将发布-3.88 的每股收益。</p>
<h2>机构资金流入和流出</h2>
<ul>
<li>Novavax 因收益未达预期而暴跌：是下跌刀还是买入机会？</li>
</ul>
<p>几家对冲基金最近增加或减少了对该股票的持股。瑞士州立银行在第一季度购买了 BioNTech 的新股份，价值约 36,000 美元。LRI Investments LLC 在第二季度将其在 BioNTech 的持股增加了 234.6%。LRI Investments LLC 现在拥有 445 股该公司的股票，价值 47,000 美元，此前在该期间内购买了 312 股。Tower Research Capital LLC TRC 在第二季度将其在 BioNTech 的持股增加了 118.2%。Tower Research Capital LLC TRC 现在拥有 563 股该公司的股票，价值 60,000 美元，此前在该期间内购买了 305 股。Hantz Financial Services Inc.在第二季度将其在 BioNTech 的持股增加了 472.0%。Hantz Financial Services Inc.现在拥有 572 股该公司的股票，价值 61,000 美元，此前在该期间内购买了 472 股。最后，GAMMA Investing LLC 在第三季度将其在 BioNTech 的持股增加了 40.8%。GAMMA Investing LLC 现在拥有 784 股该公司的股票，价值 77,000 美元，此前在该期间内购买了 227 股。15.52% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>关于 BioNTech</h2>
<p>（获取免费报告）</p>
<p>BioNTech SE 是一家生物技术公司，开发和商业化用于癌症和其他传染病的免疫疗法。该公司正在开发 FixVac 产品候选药物，包括 BNT111，该药物正在进行针对晚期黑色素瘤的二期临床试验；BNT112 正在进行针对前列腺癌的一期/二期临床试验；BNT113 正在进行针对 HPV 16+ 头颈癌的二期临床试验；BNT114 用于治疗三阴性乳腺癌；BNT115 正在进行针对卵巢癌的一期临床试验；BNT116 正在进行针对非小细胞肺癌的一期临床试验。</p>
<h2>进一步阅读</h2>
<ul>
<li>五只我们更看好的股票超过 BioNTech</li>
<li>投资优先股与普通股的比较</li>
<li>经济不确定性持续时应购买的 3 只防御性股票</li>
<li>在 P&amp;G 创下新高之前立即购买</li>
<li>3 只受益于 AI 能源激增的可持续股票</li>
<li>道琼斯工业平均指数（DJIA）是什么？</li>
<li>NVIDIA 分析师上调目标：这对股价意味着什么</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Qk5UWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Qk5UWA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审查。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 BioNTech 吗？</h2>
<p>在你考虑 BioNTech 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 BioNTech 并不在名单上。</p>
<p>虽然 BioNTech 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

BNTX

<p>Weiss Ratings 重申了对 BioNTech（NASDAQ:BNTX）股票的 “卖出（D-）” 评级。其他分析师的意见各不相同，摩根大通将其目标价上调至 121 美元，并维持 “中性” 评级，而 HC Wainwright 则设定了 136 美元的 “买入” 评级。BioNTech 的股票目前交易价格为 102.55 美元，市场共识评级为 “适度买入”，目标价格为 134.32 美元。该公司报告的收入同比增长了 102.6%，但上个季度的每股收益（EPS）未能达到预期</p>

<p>BioNTech (NASDAQ:BNTX - Get Free Report)'s stock had its &#34;sell (d-)&#34; rating reiterated by research analysts at Weiss Ratings in a research note issued to investors on Tuesday,Weiss Ratings reports.</p>
<div class="lb-trans"><p>BioNTech（纳斯达克代码：BNTX - 获取免费报告）的股票在周二发布给投资者的研究报告中被 Weiss Ratings 的研究分析师重申了 “卖出（d-）” 评级，Weiss Ratings 报道。</p>
</div><ul>
<li>4 Reasons Pfizer Could Be a Value Play You Can't Miss</li>
</ul>
<div class="lb-trans"><ul>
<li>4 个理由说明辉瑞可能是你不能错过的价值投资</li>
</ul>
</div><p>A number of other research analysts have also weighed in on the company. JPMorgan Chase &amp; Co. increased their price target on BioNTech from $116.00 to $121.00 and gave the stock a &#34;neutral&#34; rating in a research note on Monday, September 22nd. HC Wainwright reiterated a &#34;buy&#34; rating and set a $136.00 target price on shares of BioNTech in a research report on Monday, September 8th. Bank of America increased their price objective on shares of BioNTech from $126.00 to $134.00 and gave the stock a &#34;buy&#34; rating in a report on Tuesday, August 5th. Morgan Stanley cut their price objective on shares of BioNTech from $133.00 to $131.00 and set an &#34;overweight&#34; rating on the stock in a report on Friday. Finally, Wells Fargo &amp; Company set a $150.00 price target on shares of BioNTech and gave the stock an &#34;overweight&#34; rating in a research note on Tuesday, August 5th. Ten research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $134.32.</p>
<div class="lb-trans"><p>其他一些研究分析师也对该公司发表了看法。摩根大通将 BioNTech 的目标价从 116.00 美元上调至 121.00 美元，并在 9 月 22 日的研究报告中给予该股票 “中性” 评级。HC Wainwright 在 9 月 8 日的研究报告中重申了 “买入” 评级，并设定了 BioNTech 股票的目标价为 136.00 美元。美国银行在 8 月 5 日的报告中将 BioNTech 股票的目标价从 126.00 美元上调至 134.00 美元，并给予该股票 “买入” 评级。摩根士丹利在周五的报告中将 BioNTech 股票的目标价从 133.00 美元下调至 131.00 美元，并对该股票设定了 “增持” 评级。最后，富国银行在 8 月 5 日的研究报告中设定了 BioNTech 股票的目标价为 150.00 美元，并给予该股票 “增持” 评级。十位研究分析师对该股票给予了 “买入” 评级，三位给予了 “持有” 评级，一位给予了 “卖出” 评级。根据 MarketBeat 的数据，该股票的共识评级为 “适度买入”，共识目标价为 134.32 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on BioNTech</strong></p>
<div class="lb-trans"><p><strong>获取我们对 BioNTech 的最新股票分析</strong></p>
</div><h2>BioNTech Trading Up 0.2%</h2>
<div class="lb-trans"><h2>BioNTech 上涨 0.2%</h2>
</div><ul>
<li>Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?</li>
</ul>
<div class="lb-trans"><ul>
<li>Moderna 因第二季度收益下滑而下跌，但它能否因空头回补而反弹？</li>
</ul>
</div><p>NASDAQ:BNTX traded up $0.25 on Tuesday, reaching $102.55. The stock had a trading volume of 217,329 shares, compared to its average volume of 950,002. The company has a market cap of $24.65 billion, a price-to-earnings ratio of -64.21 and a beta of 1.45. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.61 and a quick ratio of 8.48. The firm's fifty day moving average is $104.32 and its two-hundred day moving average is $103.68. BioNTech has a 12-month low of $81.20 and a 12-month high of $129.27.</p>
<div class="lb-trans"><p>纳斯达克：BNTX 在周二上涨 0.25 美元，达到 102.55 美元。该股票的交易量为 217,329 股，而其平均交易量为 950,002 股。该公司的市值为 246.5 亿美元，市盈率为-64.21，贝塔值为 1.45。该公司的债务与股本比率为 0.01，流动比率为 8.61，速动比率为 8.48。该公司的 50 日移动平均线为 104.32 美元，200 日移动平均线为 103.68 美元。BioNTech 的 12 个月低点为 81.20 美元，12 个月高点为 129.27 美元。</p>
</div><p>BioNTech (NASDAQ:BNTX - Get Free Report) last released its earnings results on Monday, August 4th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.41) by ($0.19). The firm had revenue of $306.46 million during the quarter, compared to analysts' expectations of $161.26 million. BioNTech had a negative net margin of 12.20% and a negative return on equity of 1.84%. BioNTech's revenue for the quarter was up 102.6% on a year-over-year basis. During the same quarter last year, the company posted ($3.36) earnings per share. BioNTech has set its FY 2025 guidance at EPS. Equities analysts expect that BioNTech will post -3.88 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>BioNTech（纳斯达克代码：BNTX - 获取免费报告）最后一次发布财报是在 8 月 4 日，周一。该公司报告的每股收益（EPS）为-1.60 美元，低于分析师的共识预期-1.41 美元，差距为 0.19 美元。该公司在该季度的收入为 3.0646 亿美元，而分析师的预期为 1.6126 亿美元。BioNTech 的净利润率为-12.20%，股本回报率为-1.84%。BioNTech 在该季度的收入同比增长了 102.6%。去年同期，该公司每股收益为-3.36 美元。BioNTech 已设定其 2025 财年的指导目标为每股收益。股票分析师预计 BioNTech 在当前财年将发布-3.88 的每股收益。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><ul>
<li>Novavax Plunges on Earnings Miss: Falling Knife or Buying Opp?</li>
</ul>
<div class="lb-trans"><ul>
<li>Novavax 因收益未达预期而暴跌：是下跌刀还是买入机会？</li>
</ul>
</div><p>Several hedge funds have recently added to or reduced their stakes in the stock. Banque Cantonale Vaudoise purchased a new stake in shares of BioNTech during the 1st quarter valued at about $36,000. LRI Investments LLC raised its stake in shares of BioNTech by 234.6% during the second quarter. LRI Investments LLC now owns 445 shares of the company's stock valued at $47,000 after purchasing an additional 312 shares during the period. Tower Research Capital LLC TRC raised its stake in shares of BioNTech by 118.2% during the second quarter. Tower Research Capital LLC TRC now owns 563 shares of the company's stock valued at $60,000 after purchasing an additional 305 shares during the period. Hantz Financial Services Inc. raised its stake in shares of BioNTech by 472.0% during the second quarter. Hantz Financial Services Inc. now owns 572 shares of the company's stock valued at $61,000 after purchasing an additional 472 shares during the period. Finally, GAMMA Investing LLC raised its stake in shares of BioNTech by 40.8% during the third quarter. GAMMA Investing LLC now owns 784 shares of the company's stock valued at $77,000 after purchasing an additional 227 shares during the period. 15.52% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>几家对冲基金最近增加或减少了对该股票的持股。瑞士州立银行在第一季度购买了 BioNTech 的新股份，价值约 36,000 美元。LRI Investments LLC 在第二季度将其在 BioNTech 的持股增加了 234.6%。LRI Investments LLC 现在拥有 445 股该公司的股票，价值 47,000 美元，此前在该期间内购买了 312 股。Tower Research Capital LLC TRC 在第二季度将其在 BioNTech 的持股增加了 118.2%。Tower Research Capital LLC TRC 现在拥有 563 股该公司的股票，价值 60,000 美元，此前在该期间内购买了 305 股。Hantz Financial Services Inc.在第二季度将其在 BioNTech 的持股增加了 472.0%。Hantz Financial Services Inc.现在拥有 572 股该公司的股票，价值 61,000 美元，此前在该期间内购买了 472 股。最后，GAMMA Investing LLC 在第三季度将其在 BioNTech 的持股增加了 40.8%。GAMMA Investing LLC 现在拥有 784 股该公司的股票，价值 77,000 美元，此前在该期间内购买了 227 股。15.52% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>About BioNTech</h2>
<div class="lb-trans"><h2>关于 BioNTech</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.</p>
<div class="lb-trans"><p>BioNTech SE 是一家生物技术公司，开发和商业化用于癌症和其他传染病的免疫疗法。该公司正在开发 FixVac 产品候选药物，包括 BNT111，该药物正在进行针对晚期黑色素瘤的二期临床试验；BNT112 正在进行针对前列腺癌的一期/二期临床试验；BNT113 正在进行针对 HPV 16+ 头颈癌的二期临床试验；BNT114 用于治疗三阴性乳腺癌；BNT115 正在进行针对卵巢癌的一期临床试验；BNT116 正在进行针对非小细胞肺癌的一期临床试验。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than BioNTech</li>
<li>Investing In Preferred Stock vs. Common Stock</li>
<li>3 Defensive Stocks to Buy as Economic Uncertainty Lingers</li>
<li>Buy P&amp;G Now, Before It Sets A New All-Time High</li>
<li>3 Sustainable Stocks Benefiting From the AI Energy Surge</li>
<li>What is the Dow Jones Industrial Average (DJIA)?</li>
<li>NVIDIA Analysts Lift Targets: What It Means for the Stock Price</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 BioNTech</li>
<li>投资优先股与普通股的比较</li>
<li>经济不确定性持续时应购买的 3 只防御性股票</li>
<li>在 P&amp;G 创下新高之前立即购买</li>
<li>3 只受益于 AI 能源激增的可持续股票</li>
<li>道琼斯工业平均指数（DJIA）是什么？</li>
<li>NVIDIA 分析师上调目标：这对股价意味着什么</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Qk5UWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=BNTX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审查。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in BioNTech Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 BioNTech 吗？</h2>
</div><p>Before you consider BioNTech, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 BioNTech 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioNTech wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 BioNTech 并不在名单上。</p>
</div><p>While BioNTech currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 BioNTech 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Weiss Ratings 重申了对 BioNTech SE（BNTX）的 “卖出（D-）” 评级